Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$139.88 USD

139.88
1,728,309

+1.11 (0.80%)

Updated Aug 8, 2025 03:59 PM ET

After-Market: $139.88 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research

Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

Zacks Equity Research

Here's Why You Should Hold onto Varian Medical (VAR) Stock Now

Investor confidence is high on Varian Medical (VAR) stock, courtesy of solid prospects.

Trina Mukherjee headshot

Grab 3 Dental Stocks More Than Doubling Industry Gains for 2021

Buy these three top dental stocks that have shown sharp recovery despite market volatility due to the pandemic, and have the potential to continue their bull run in 2021.

Zacks Equity Research

Veeva (VEEV) Vault QMS Gets Picked by Samsung Biologics

Veeva Systems' (VEEV) Vault Quality Suite gets selected by Samsung Biologics to drive quality process and content management for better visibility across the latter's global processes.

    Zacks Equity Research

    PDCO or ALGN: Which Is the Better Value Stock Right Now?

    PDCO vs. ALGN: Which Stock Is the Better Value Option?

    Zacks Equity Research

    Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

    AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

      Zacks Equity Research

      NextGen's (NXGN) HDH to Facilitate Health Information Exchange

      NextGen's (NXGN) HDH has been chosen by HI-BRIDGE HIE for secure sharing of patient health data from multiple sources.

        Zacks Equity Research

        Masimo (MASI) Releases Favorable Findings on Pulse Oximetry

        Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.

        Zacks Equity Research

        Here's Why You Should Retain Fresenius Medical (FMS) Stock

        Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.

        Zacks Equity Research

        Cerner's (CERN) Simplified Digital Tools to Aid Health Systems

        Cerner (CERN) offers centralized digital ordering and monitoring for clients in order to help health systems.

        Zacks Equity Research

        Here's Why You Should Hold on to McKesson (MCK) Stock Now

        McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

        Zacks Equity Research

        Simbec-Orion to Adopt Veeva's (VEEV) Vault Applications

        Veeva's (VEEV) clinical solutions will offer Simbec-Orion real-time insights into studies in phases to accelerate trial execution.

        Zacks Equity Research

        Cerner's (CERN) Deal to Make Clinical Trials More Accessible

        Cerner (CERN) inks deal with Elligo Health Research to make clinical trials more accessible, while minimizing costs.

        Zacks Equity Research

        Here's Why You Should Hold on to Nevro (NVRO) Stock Now

        Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.

        Zacks Equity Research

        HealthEquity (HQY) Q3 Earnings and Revenues Beat Estimates

        HealthEquity (HQY) delivers strong growth in Service, Custodial and Interchange segments in Q3.

        Zacks Equity Research

        Here's Why You Should Retain Change Healthcare (CHNG) Stock

        Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.

        Zacks Equity Research

        NextGen (NXGN) Reinforces Its Robust Solutions Portfolio

        NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.

        Zacks Equity Research

        Veeva (VEEV) Vault Applications Get Adopted by GenesisCare

        Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.

        Zacks Equity Research

        Baxter's (BAX) Vital Edge Program Aids Patient Blood Management

        Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.

        Zacks Equity Research

        Here's Why You Should Retain LHC Group (LHCG) Stock Now

        LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.

        Zacks Equity Research

        Cooper Companies (COO) Q4 Earnings & Revenues Top Estimates

        Cooper Companies' (COO) fiscal fourth-quarter earnings reflect weak segmental performance. However, it exceeds expectation as it witnesses faster-than-anticipated recovery.

        Zacks Equity Research

        Here's Why You Should Invest in Cardinal Health (CAH) Stock

        Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and buyouts.

        Zacks Equity Research

        Why You Should Retain Pacific Biosciences (PACB) Stock Now

        Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.

        Zacks Equity Research

        Zimmer Biomet (ZBH) Boosts Portfolio With A&E Medical Buyout

        This latest development aligns with Zimmer Biomet's (ZBH) active portfolio management strategy and the ongoing transformation of business aimed at long-term growth.